Go Pro
→ Do this before December or regret it (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$3.95
+5.9%		$3.86
$3.13
▼
$7.20
$7.19M1.0918,826 shs77,077 shs
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
$0.66
-2.0%		$0.75
$0.59
▼
$3.15
$29.27M0.8833,531 shs25,925 shs
NextCure, Inc. stock logo
NXTC
NextCure
$7.00
-4.2%		$5.77
$1.55
▼
$15.74
$26.40M1.33109,457 shs115,256 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$0.32
+0.8%		$0.76
$0.31
▼
$2.57
$21.55M1.071.01 million shs873,124 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
+5.90%+1.28%+14.49%-13.38%-24.90%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
-1.99%+2.06%-10.88%-37.77%-37.77%
NextCure, Inc. stock logo
NXTC
NextCure
-4.24%-10.49%-14.32%+236.54%+27.50%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
+0.79%-18.16%-58.55%-64.87%-82.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$3.95
+5.9%		$3.86
$3.13
▼
$7.20
$7.19M1.0918,826 shs77,077 shs
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
$0.66
-2.0%		$0.75
$0.59
▼
$3.15
$29.27M0.8833,531 shs25,925 shs
NextCure, Inc. stock logo
NXTC
NextCure
$7.00
-4.2%		$5.77
$1.55
▼
$15.74
$26.40M1.33109,457 shs115,256 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$0.32
+0.8%		$0.76
$0.31
▼
$2.57
$21.55M1.071.01 million shs873,124 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
+5.90%+1.28%+14.49%-13.38%-24.90%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
-1.99%+2.06%-10.88%-37.77%-37.77%
NextCure, Inc. stock logo
NXTC
NextCure
-4.24%-10.49%-14.32%+236.54%+27.50%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
+0.79%-18.16%-58.55%-64.87%-82.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
2.25
Hold$14.50267.09% Upside
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
2.00
Hold$8.001,112.86% Upside
NextCure, Inc. stock logo
NXTC
NextCure
2.25
Hold$19.00171.43% Upside
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
2.13
Hold$2.67732.29% Upside

Current Analyst Ratings Breakdown

Latest BOLT, NXTC, ESLA, and TCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/8/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/8/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral$1.00
9/2/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral$1.00
9/2/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Lifesci Capital logo
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/26/2026
NextCure, Inc. stock logo
NXTC
NextCure
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/25/2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/13/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/13/2026
NextCure, Inc. stock logo
NXTC
NextCure
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/12/2026
NextCure, Inc. stock logo
NXTC
NextCure
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/12/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$7.70M0.99N/AN/A$13.81 per share0.29
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/AN/AN/AN/A($0.27) per shareN/A
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/A$9.97 per shareN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$7.11M3.05N/AN/A$2.16 per share0.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$33.38M-$16.44N/AN/AN/A-611.47%-126.23%-54.70%11/11/2026 (Estimated)
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
-$13.06M-$0.24N/AN/AN/AN/AN/A-328.72%N/A
NextCure, Inc. stock logo
NXTC
NextCure
-$55.84M-$8.70N/AN/AN/AN/A-154.62%-100.19%11/4/2026 (Estimated)
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$129.77M-$0.91N/AN/AN/A-1,655.35%-108.72%-54.47%11/11/2026 (Estimated)

Latest BOLT, NXTC, ESLA, and TCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
-$0.09-$0.05+$0.04-$0.05N/AN/A
8/12/2026Q2 2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.2534-$0.23+$0.0234-$0.23$1.88 million$1.05 million
8/11/2026Q2 2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$3.39-$4.57-$1.18-$4.57$0.50 million$0.01 million
8/6/2026Q2 2026
NextCure, Inc. stock logo
NXTC
NextCure
-$1.95-$2.80-$0.85-$2.80N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
N/AN/AN/AN/AN/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/AN/AN/AN/AN/A
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
1.47
2.61
2.61
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/A
0.20
0.20
NextCure, Inc. stock logo
NXTC
NextCure
N/A
3.47
3.47
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.31
3.37
3.37

Institutional Ownership

CompanyInstitutional Ownership
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
86.70%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
0.35%
NextCure, Inc. stock logo
NXTC
NextCure
42.65%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%

Insider Ownership

CompanyInsider Ownership
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
9.40%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
5.80%
NextCure, Inc. stock logo
NXTC
NextCure
11.90%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
6.25%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
901.93 million1.75 millionNot Optionable
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/A43.50 million40.98 millionNot Optionable
NextCure, Inc. stock logo
NXTC
NextCure
903.61 million3.18 millionNo Data
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
10067.78 million63.54 millionNot Optionable

Recent News About These Companies

HC Wainwright Issues Optimistic Estimate for TCRX Earnings
September 12 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31017670
TScan Therapeutics (NASDAQ:TCRX) Stock Rating Lowered by HC Wainwright
September 10 at 1:24 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31013718
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from Brokerages
September 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31007781
Wedbush downgrades TScan Therapeutics (TCRX) to neutral from outperform
September 3, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/wedbush-downgrades-tscan-therapeutics-tcrx-to-neutral-from-outperform/ar-AA2bwA9B
TScan Therapeutics Reorganizes To Focus On Solid Tumor Program; To Cut 75% Jobs; Stock Tumbles 11%
September 2, 2026  |  rttnews.comhttps://www.rttnews.com/3687878/tscan-therapeutics-reorganizes-to-focus-on-solid-tumor-program-to-cut-75-jobs-stock-tumbles-11.aspx
TScan Therapeutics cuts workforce by 75% and shifts focus to solid tumor program
September 2, 2026  |  msn.comhttps://www.msn.com/en-us/science/general/tscan-therapeutics-cuts-workforce-by-75-and-shifts-focus-to-solid-tumor-program/ar-AA2bqfIn
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction
September 2, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/09/61580674/tscan-reorganizes-pipeline-priorities-implements-workforce-reduction
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3354974/0/en/tscan-therapeutics-announces-strategic-reorganization-to-focus-on-in-vivo-cell-therapy-for-solid-tumors.html
Equities Analysts Set Expectations for TCRX FY2026 Earnings
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/equities-analysts-set-expectations-for-tcrx-fy2026-earnings-2026-08-14/
Analysts Offer Insights on Healthcare Companies: Immix Biopharma (IMMX), TScan Therapeutics (TCRX) and enGene Holdings (ENGN)
August 13, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IMMX/pressreleases/3830638/analysts-offer-insights-on-healthcare-companies-immix-biopharma-immx-tscan-therapeutics-tcrx-and-engene-holdings-engn/
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Brokerages
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tscan-therapeutics-inc-nasdaqtcrx-given-average-rating-of-hold-by-brokerages-2026-08-13/
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
August 12, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2973293/tscan-therapeutics-inc-tcrx-reports-q2-loss-misses-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2973293
TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results
August 12, 2026  |  quiverquant.comQ
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/12/3343490/0/en/tscan-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335095/0/en/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies.html
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/24/3316713/0/en/tscan-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-cell-therapy-virtual-conference.html
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic ...
June 23, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/tscan-therapeutics-announces-positive-initial-data-from-cohort-c-of-ongoing-alloha-phase-1-study-evaluating-tsc-101-in-patients-with-heme-malignancies-undergoing-allogeneic-hematopoietic-cell-1036264745
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
June 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/22/3315162/0/en/tscan-therapeutics-announces-positive-initial-data-from-cohort-c-of-ongoing-alloha-phase-1-study-evaluating-tsc-101-in-patients-with-heme-malignancies-undergoing-allogeneic-hematop.html
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
June 3, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260603703141/en/cellares-and-tscan-therapeutics-announce-agreement-to-evaluate-automated-manufacturing-of-tsc-101-for-patients-with-hematologic-malignancies/
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss
June 2, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/tscan-therapeutics-inc-tcrx-reports-q1-2026-results-with-improved-net-loss-1773515/
TScan Therapeutics Expands Authorized Shares After Stockholder Vote
May 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tscan-therapeutics-expands-authorized-shares-after-stockholder-vote?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A gold futuristic electric concept car parked on a street with a city skyline and capitol dome at dusk.
Tesla's Cybercab Launch Could Reshape Margins for Uber and Lyft
By Jeffrey Neal Johnson | August 19, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Red Tesla vehicle parked beside a building displaying the Tesla logo, with mountains in the background.
Can Tesla’s Flying Roadster Distract From Its Real Risks?
By Sam Quirke | August 26, 2026
A Zoox autonomous vehicle drives on a city street in front of an Amazon office building with logo.
Amazon’s Zoox Push Tests Tesla’s Robotaxi Premium as Waymo Widens Its Lead
By Sam Quirke | August 29, 2026
Gold-colored concept electric vehicle with a smooth, minimalist body parked outdoors near a building and tree.
Ride-Share Reckoning: Tesla Drives Into Uber's Lane
By Jeffrey Neal Johnson | September 7, 2026
Bolt Biotherapeutics stock logo

Bolt Biotherapeutics NASDAQ:BOLT

$3.95 +0.22 (+5.90%)
Closing price 09/11/2026 03:54 PM Eastern
Extended Trading
$3.86 -0.10 (-2.41%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Estrella Immunopharma stock logo

Estrella Immunopharma NASDAQ:ESLA

$0.66 -0.01 (-1.99%)
Closing price 09/11/2026 03:59 PM Eastern
Extended Trading
$0.68 +0.02 (+3.40%)
As of 09/11/2026 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

NextCure stock logo

NextCure NASDAQ:NXTC

$7.00 -0.31 (-4.24%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$7.20 +0.21 (+2.93%)
As of 09/11/2026 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$0.32 +0.00 (+0.79%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$0.32 0.00 (-0.75%)
As of 09/11/2026 06:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas